Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs

Vericat, J.E. Megías; Marcos, R. García; Briz, Eduardo López; Muñoz, F.; Ruiz, Jenny; Rodrigo, J.J. Martínez; Andrés, José Luís Poveda

doi:10.1016/j.rxeng.2015.09.004

Cited by 14 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective study from Germany, there was no difference of median survival between two groups (409 days in cTACE vs 369 days in DEB‐TACE, P = 0.39) . Similarly, in recent studies from Spain and Saudi Arabia, DEB‐TACE did not show a superiority to cTACE in terms of OS …”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Conventional versus drug‐eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size

Lee

Jung

Kim

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

“…In a recent study from Spain, overall mean cost of intervention was higher in DEB‐TACE group than in cTACE group. However, the author insisted that tolerance of DEB‐TACE might justify higher costs of the procedure despite comparable OS …”

Section: Discussionmentioning

confidence: 99%

Conventional versus drug‐eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size

Lee

Jung

Kim

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…11 -13,23,24 However, the objective clinical benefit of DEB-TACE compared to cTACE are still controversial, and a great amount of studies illuminated that DEB-TACE does not improve the clinical response or survival compared to cTACE but achieves fewer procedures, less liver toxicity benefit, better tolerance, and shorter hospital stay. 18,21,25 -29 While another 2 studies in Asia inversely illuminate that DEB-TACE elevates treatment response, postpones the progression, and prolongs OS when compared to cTACE. 30,31 The main cause of this controversy might result from the gap of technical ability between non-Asian physicians and Asian physicians in performing cTACE.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer

Chen

Zheng

et al. 2018

Technol Cancer Res Treat

View full text Add to dashboard Cite

This study aimed to investigate the clinical response and short-term survival and further explore the comprehensive factors for predicting clinical outcomes in patients with liver cancer treated by drug-eluting beads transarterial chemoembolization . Forty-nine patients with liver cancer who received drug-eluting beads transarterial chemoembolization treatment were consecutively enrolled in this cohort study. Demographic features, medical histories, clinicopathological properties, biochemical indexes, previous treatments, and chemoembolization reagents were recorded. Ten (20.4%) patients achieved complete response and 31 (63.3%) patients achieved partial response after drug-eluting beads transarterial chemoembolization treatment, with overall response rate of 83.7%. Logistic analysis revealed that high aspartate aminotransferase (P = .041), high carbohydrate antigen 199 (P = .030), and low hemoglobin (P = .020) could independently predict less possibility for complete response achievement. As to survival analysis, high alkaline phosphatase (P = .040), low albumin (P = .033) low hemoglobin (P = .018), portal vein invasion (P = .025), higher Eastern Cooperative Oncology Group performance status (P = .011), and higher Child-pugh stage (P = .001) were independent predictors for worse overall survival. In conclusion, the present study validated that drug-eluting beads transarterial chemoembolization was effective and well tolerated for patients with liver cancer, and high aspartate aminotransferase, high alkaline phosphatase, low albumin, low hemoglobin, portal vein invasion, higher Child-pugh stage, higher Barcelona Clinic Liver Cancer stage, higher Eastern Cooperative Oncology Group performance status were correlated with worse outcomes.

show abstract

“…4 Overall, per-patient, healthcare resource group-based cost estimates of SIR-Spheres Y-90 resin microspheres, workup, and selective internal radiation therapy procedure with and without the order-map-treat program load to be reduced) while patients are waiting for evaluation or access to other therapies; such adaptable treatment pathways are particularly beneficial during global health crises such as the COVID-19 pandemic, but are also clearly advantageous in routine practice [43]. OMT increases this aspect by enabling single-stay treatment of HCC, compared to systemic therapies or chemoembolization which generally require several hospitalizations, sometimes lasting multiple days [44,45]. It is aligned with the recommendation to conduct the SIRT procedure as soon as possible after the work-up [46].…”

Section: Discussionmentioning

confidence: 99%

Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England

Pollock

Shergill²,

Carion

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Introduction Selective internal radiation therapy (SIRT) is a targeted method of treatment for unresectable liver tumors in which radiation therapy is directly delivered to the tumor(s) via the hepatic vasculature. Successful outcomes with SIRT are dependent on the specific vasculature of the liver and tumor, and the patient therefore needs to attend a “work-up” to map the hepatic vasculature prior to the SIRT procedure. Recent advances in SIRT delivery have enabled same-day or same-stay work-up and procedure, requiring only one hospital visit rather than two. We aimed to evaluate the economic, travel time, and transport-related environmental impact of a new brachytherapy device delivery program, the order-map-treat (OMT) program, in patients with unresectable hepatocellular carcinoma (HCC) in England. Methods A healthcare resource group (HRG)-based analysis of costs from a national payer (Department of Health and Social Care, DHSC) perspective was conducted assuming that, with OMT, patients would have to attend hospital only once for both the SIRT work-up and procedure versus twice without OMT. Patient travel time and CO 2 emissions were then estimated by identifying the SIRT center closest to the centroid of each clinical commissioning group (CCG) and calculating straight-line distances with a “detour index” to capture the effect of indirect routes via road or rail. Results It was estimated that 856 patients per annum would be eligible for SIRT treatment for unresectable HCC in England. OMT would be anticipated to save GBP 2842 per patient versus performing SIRT without OMT. Furthermore, across all patients with HCC eligible for SIRT in England, OMT would avoid 74,500 km of travel, 2299 h of travel time, and 13.9 metric tons of patient transport-related CO 2 emissions annually. Conclusion OMT reduces the number of hospital visits required for SIRT by 50%, resulting in financial savings from the DHSC perspective, time savings from the patient perspective, and reduced CO 2 emissions arising from patient transport. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02323-x.

show abstract

Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs

Cited by 14 publications

References 33 publications

Conventional versus drug‐eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size

Conventional versus drug‐eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size

Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer

Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England

Contact Info

Product

Resources

About